12:00 AM
 | 
Oct 01, 2007
 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch

Date Company Staff cuts Cash Years cash pre-cut Cash date 1H07 oper loss
7/18/07 pSivida (ASX:PSD; PSDV) >30% A$27.1 (A) 0.48 6/30/07 A$55.6 (A)(B)
Discontinues undisclosed early stage research; and transitions to a drug delivery company from a nano-biomaterials company
7/20/07 Nabi (NABI) 5% to 575 $103.9 3.29 6/30/07 $15.8
Headcount reduction in connection with a reorganization to support the new Nabi Pharmaceuticals business unit; the restructuring is expected to provide $3.3M in annual savings
7/25/07 Aspreva (TSX:ASV; ASPV) 25% to 100 NA NA NA Profitable
Cuts mainly in clinical and sales positions and include CSO Richard Jones; considers its options for autoimmune programs...

Read the full 678 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >